The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis

勋; 张锡友; 峰; 李丹丹; 董倩倩; 宋清坤; 钟晓松; 李文斌

doi:10.19401/j.cnki.1007-3639.2019.08.002

您当前的位置：

首页 >

文章列表页 >

The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis

更新时间：2026-01-27

- The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis
- China Oncology Vol. 29, Issue 8, Pages: 568-575(2019)
- 作者机构：
  
  1. 首都医科大学附属北京天坛医院神经肿瘤综合治疗病区,北京,100050
  2. 首都医科大学附属北京世纪坛医院脑胶质瘤科,北京,100038
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.08.002
  CLC： R733.1
- Published Online：29 September 2019，
  
  Published：29 September 2019
- 稿件说明：
移动端阅览
康?勋,张锡友,陈? 峰,李丹丹,董倩倩,宋清坤,钟晓松,李文斌 . CAR-T治疗B细胞淋巴瘤不良反应的Meta分析[J]. 中国癌症杂志, 2019, 29(8): 568-575.

勋, 张锡友, 峰, et al. The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis[J]. China Oncology, 2019, 29(8): 568-575.
康?勋,张锡友,陈? 峰,李丹丹,董倩倩,宋清坤,钟晓松,李文斌 . CAR-T治疗B细胞淋巴瘤不良反应的Meta分析[J]. 中国癌症杂志, 2019, 29(8): 568-575. DOI： 10.19401/j.cnki.1007-3639.2019.08.002.

勋, 张锡友, 峰, et al. The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis[J]. China Oncology, 2019, 29(8): 568-575. DOI： 10.19401/j.cnki.1007-3639.2019.08.002.

摘要

背景与目的：复发、难治性B细胞淋巴瘤患者常规治疗方案难以奏效，研究新的治疗技术和改善预后迫在眉睫。近年来，嵌合抗原受体T细胞（chimeric antigen receptor T-cell，CAR-T）技术在B细胞淋巴瘤治疗中的突破，为复发、难治性B细胞淋巴瘤患者带来了新的希望。探讨在CAR-T技术治疗B细胞淋巴瘤的过程中，细胞因子释放综合征（cytokine release syndrome，CRS）和神经毒性等不良反应的发生率，为更加合理、安全地应用CAR-T提供理论依据。方法：检索PubMed数据库和Cochrane Library数据库的英文文献，研究从建库至2018年1月为止公开发表的CAR-T治疗B细胞淋巴瘤的10篇文献。发生率作为结局指标，按照不良反应（CRS和神经毒性）的不同，采用Meta分析汇总发生率。结果：CAR-T治疗B细胞淋巴瘤的过程中CRS的总发生率为57%（95% CI：0.25~0.90），神经毒性的总发生率为48%（95% CI：0.30~0.66）。结论：CAR-T治疗B细胞淋巴瘤的过程中CRS和神经毒性均有较高的发生率，需要引起足够重视。

Abstract

Background and purpose: For patients with relapsed or refractory B-cell lymphoma

conventional therapy is not effective. Researching new treatment technology to improve prognosis is imminent. Chimeric antigen receptor T-cell (CAR-T) technology has high safety and remission rate in B-cell lymphoma. The incidence rates of cytokine release syndrome (CRS) and neurological toxicity in the treatment of B-cell lymphoma with CAR-T were investigated in this study

so as to provide guidance for CAR-T in the treatment of lymphoma. Methods: Following comprehensive retrieval of PubMed database and the Cochrane Library database in English literature

a quantitative and comprehensive analysis was conducted for ten articles regarding CAR-T in the treatment of B-cell lymphoma that were published from the establishment of the databases to Jan

2018. The incidence rate was used as the outcome. According to the difference of toxicity

Meta-analysis of the incidence rate was performed. Results: The total incidence rate of CRS in B-cell lymphoma treated with CAR-T was 57% (95% CI: 0.25-0.90)

while the total incidence rate of neurological toxicity in B-cell lymphoma treated with CAR-T was 48% (95% CI: 0.30-0.66). Conclusion: The incidence rates of CRS and neurological toxicity in B-cell lymphoma treated with CAR-T are both high.

关键词

Keywords

references

Views

2433

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

New advances in lymphoma pathology

Risk of cancer therapy-related cardiotoxicity following the use of PD-1/PD-L1 inhibitors combined with chemoradiotherapy compared with chemoradiotherapy in solid tumors: a systematic review and Meta-analysis

Microwave ablation versus hepatic resection in potentially resectable colorectal liver metastasis: a systematic review and meta-analysis

Survival impact of corticosteroid and immunosuppressant management strategies for immune-related adverse events in immune checkpoint inhibitor-treated patients: a systematic review and meta-analysis

A meta-analysis of the efficacy of ⁹⁹Tc-MDP alone and in combination with ⁸⁹SrCl₂ in the treatment of bone metastases

Related Author

李小秋

SU Qiang

WANG Mingxuan

ZHENG Jinmei

WU Wanghui

ZHENG Jimei

WU Fei

LIU Ji

Related Institution

复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系

Department of Emergency, Beijing Friendship Hospital Capital Medical University

Zhangzhou Changtai District Hospital

Department of Pathology, School of Basic Medical Sciences of Fujian Medical University

Department of Oncology, Beijing Friendship Hospital Capital Medical University

AI问答

⁰